MetaBloQ is a privately held biotechnology company based in Melbourne, Australia. The company is focused on the discovery and development of new drugs to treat difficult-to-treat cancers such as triple-negative breast cancer, prostate cancer and melanoma. Our unique approach targets metabolic processes specific to cancer cells so that our drugs will have minimal toxicity to normal healthy tissues.